Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBS2418 in advanced colorectal cancer
NCT06824064Phase 2
Key facts
- Status
- Recruiting
- Start
- Jan 2025
- Primary completion
- Dec 2027
- Countries
- 3
- Sponsor
- Riboscience LLC
- Modality
- Prophylactic Vaccines, Small Molecules, Therapeutic Vaccines
- Drugs
- rbs2418
- Conditions
- colorectal cancer (CRC)
01
Overview
Phase 2, randomised, double-blind trial of rbs2418 in colorectal cancer (CRC) (4 arms), sponsored by Riboscience LLC. Primary endpoints: Progression-Free Survival at 2 years and Overall Survival at 2 years. Started Jan 2025; status: recruiting.
02
Design
4 arms- Study design
- RandomizedDouble-blind
Group A: EG+ RBS2418 + BSC
RBS2418 200 mg PO BID plus Best Supportive Care
Group B: EG+ Placebo + BSC
Placebo PO BID plus Best Supportive Care
Group C: EG- RBS2418 + BSC
RBS2418 200 mg PO BID plus Best Supportive Care
Group D: EG- Placebo + BSC
Placebo PO BID plus Best Supportive Care
03
Who it enrols
Adults with advanced, metastatic, progressive colorectal cancer who have failed or are ineligible for standard of care therapies, with measurable disease, ECOG 0-2, and life expectancy >= 3 months.
04
Endpoints
Primary
Progression-Free Survival
Overall Survival
Secondary
Duration of Response
Disease Control Rate
Beyond the preview
Go deeper on NCT06824064.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06824064.